Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
Haemophilia · 2023
DOI: 10.1111/hae.14818 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Haemophilia, 2023. Verfasst von Jan Astermark und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Hemophilia A. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BioMarin Pharmaceutical.
Abstract (Originalsprache)
Introduction
Head‐to‐head evaluation of valoctocogene roxaparvovec, the first gene therapy approved for haemophilia A, with emicizumab is not available. Therefore, phase 3 trial data were indirectly compared.
Aim
To compare bleeding rates in trials evaluating 6 × 10 13 vg/kg valoctocogene roxaparvovec (GENEr8‐1; NCT03370913), 1.5 mg/kg emicizumab dosed every week (HAVEN 3; NCT02847637), and FVIII prophylaxis (270–902) in participants with severe haemophilia A (FVIII ≤1 IU/dL).
Methods
Valoctocogene roxaparvovec versus emicizumab and FVIII prophylaxis as used in 270–902 versus emicizumab cross‐trial comparisons were performed using matching‐adjusted indirect comparison (MAIC). Individual participant data from GENEr8‐1 and 270–902 were weighted to equalise aggregate participant baseline characteristics from HAVEN 3. After MAIC weighting, annualised bleeding rates (ABR) and proportions of participants without bleeds were compared for treated bleeds, all bleeds, treated joint bleeds, and treated spontaneous bleeds.
Results
After MAIC weighting, ABR for all bleeds was statistically significantly lower with valoctocogene roxaparvovec than emicizumab (rate ratio [95% CI], .55 [.33–.93]). Additionally, significantly higher proportions of participants had no treated joint bleeds (odds ratio [95% CI], 2.75 [1.20–6.31]) and no treated bleeds (3.25 [1.53–6.90]) with valoctocogene roxaparvovec versus emicizumab. When compared with the mainly standard half‐life FVIII prophylaxis regimens in 270–902, mean ABRs (except for all bleeds) were significantly lower, and significantly higher proportions reported 0 bleeds for all outcomes with emicizumab.
Conclusion
Valoctocogene roxaparvovec provided generally lower bleeding rates and higher probability of no bleeds, including treated joint bleeds, than emicizumab. Emicizumab was more effective than FVIII prophylaxis regimens used in 270–902.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, Lund University, Lund, Sweden.
- Department for Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
- University of Colorado School of Medicine Hemophilia and Thrombosis Center, Aurora, Colorado, USA.
- Centre de Traitement de l'Hemophilie, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Paris, France.
- Delta Hat Limited, Nottingham, UK.
- Department of Statistics, University College London, London, UK.
ORCID-Profile: Jan Astermark, Laurent Frenzel, Robert Klamroth
Förderung
- BioMarin Pharmaceutical
Zitieren
APA
Astermark, J., Buckner, T. W., Frenzel, L., Hatswell, A. J., You, X., Liu, H., Goodman, E., Santos, S., Hawes, C., Hinds, D., & Klamroth, R. (2023). Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. https://doi.org/10.1111/hae.14818
Vancouver
Astermark J, Buckner TW, Frenzel L, Hatswell AJ, You X, Liu H, et al. Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis. Haemophilia. 2023. doi:10.1111/hae.14818
BibTeX
@article{Astermark2023,
author = {Astermark, Jan and Buckner, Tyler W and Frenzel, Laurent and Hatswell, Anthony J and You, Xiaojun and Liu, Hai and Goodman, Erin and Santos, Sandra and Hawes, Charles and Hinds, David and Klamroth, Robert},
title = {Matching‐adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14818}
}
EUVIMED